Abstract 1317P
Background
The real-world LIST study aims to describe patient (pt) characteristics, effectiveness, safety and IO rechallenge outcomes of NIV treatment in French pts with aNSCLC.
Methods
LIST is an ongoing longitudinal, prospective, observational study in pts with aNSCLC receiving NIV after at least one chemotherapy (CT) alone or with IO. It includes pts who are IO-naïve (Cohort 1), IO-experienced and discontinued due to reasons other than IO-toxicity (Cohort 2) and IO-experienced and discontinued due to IO-toxicity (Cohort 3). The primary endpoint is the time to treatment discontinuation (TTD). Interim results with ≥6 months (mo) follow-up are reported.
Results
At data cut-off (Dec 2023), 522 pts were enrolled (279/ 197/ 46 pts in Cohorts 1/ 2/ 3; median age 70/ 66/ 66.5 years, 68.5%/ 62.9%/ 78.3% male, 89.6%/ 88.3%/ 95.7% past/current smokers, 60.6%/ 76.1%/ 73.9% non-squamous histology, 74.2%/ 75.6%/ 67.4% Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0–1 at NIV initiation). At 6 mo, respective event-free rates for TTD were 35.3%/ 24.5%/ 31.6%; the main reason for discontinuation was disease progression. Numerically higher event-free rates were observed in pts with ECOG PS 0–1, fewer prior systemic therapy lines, longer prior IO duration, prolonged benefit with prior IO or if only prior IO (±CT) was NIV (Table). All grade treatment-related adverse events (TRAEs) were reported in 36.6%/24.5%/35.4% and grade 3/4 TRAEs in 7.5%/3.0%/12.5% of pts in Cohorts 1/ 2/ 3 respectively. Table: 1317P
Event-free rate for TTD at 6 mo, overall and by subgroup
| Cohort 1 | Cohort 2 | Cohort 3 | ||||
| n | Rate, % | n | Rate, % | n | Rate, % | |
| Overall | 279 | 35.3 | 197 | 24.5 | 46 | 31.6 |
| Subgroups | ||||||
| ECOG PS at NIV initiation | ||||||
| 0–1 | 207 | 38.9 | 149 | 29.2 | 31 | 38.7 |
| ≥2 | 72 | 25.0 | 48 | 9.6 | 15 | 15.2 |
| Last IO duration, months | ||||||
| 12 | – | – | 68 | 33.1 | 12 | 45.8 |
| Only prior IO (± CT) is NIV | – | – | 49 | 35.2 | 13 | 42.3 |
| Prior systemic therapy lines | ||||||
| 1 | 219 | 38.1 | 9 | 55.6 | 10 | 40.0 |
| 2 | 40 | 21.3 | 67 | 27.9 | 20 | 32.7 |
| ≥3 | 8 | 28.6 | 120 | 20.3 | 16 | 25.0 |
| Reason for last IO discontinuation | ||||||
| Progression | – | – | 166 | 21.5 | – | – |
| Prolonged benefit | – | – | 15 | 59.3 | – | – |
| PD-L1 expression | ||||||
ConclusionsLIST interim results show similar outcomes in IO-naïve pts as Checkmate 017/057, and promising effectiveness and safety of IO rechallenge in IO-experienced pts, especially in specific subgroups. Moreover, IO rechallenge results in pts who discontinued their prior IO due to IO-toxicity seem to be consistent with the safety profile of NIV. Clinical trial identificationNCT04500535. Editorial acknowledgementWe thank Sarah Greig, PhD, CMPP of Springer Healthcare who wrote the first draft of the congress abstract under guidance from the authors. This medical writing assistance was funded by Bristol Myers Squibb. Legal entity responsible for the studyBristol Myers Squibb. FundingBristol Myers Squibb. DisclosureB. Godbert: Financial Interests, Institutional, Advisory Board: MSD, AstraZeneca, BMS, Sanofi, Janssen; Financial Interests, Institutional, Local PI: MSD, BMS, Roche; Financial Interests, Institutional, Coordinating PI: AstraZeneca; Non-Financial Interests, Institutional, Other, Congress invitation: Pfizer. E. Gobbini: Other, Personal, Advisory Board: Janssen; Non-Financial Interests, Institutional, Local PI: Janssen; Other, Personal, Non financial benefits: Takeda, Sanofi; Non-Financial Interests, Institutional, Funding: BMS, AstraZeneca; Non-Financial Interests, Personal, Other: AstraZeneca; Non-Financial Interests, Personal, Invited Speaker: Sanofi, BMS. C. Decroisette: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Advisory Board: BMS, MSD, Takeda, Sanofi, AstraZeneca, Pfizer, Amgen. H. Lena: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb. D. Moro-Sibilot: Financial Interests, Personal, Advisory Board: BMS. F. Guisier: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, MSD, Roche, Sanofi, Janssen, Pfizer, Takeda; Financial Interests, Institutional, Research Grant: Pfizer, Roche, Takeda. S. Couraud: Non-Financial Interests, Personal, Non remunerated activity: Adene; Financial Interests, Personal and Institutional, Advisory Board: Amgen, BMS, Boehringer Ingelheim, MSD, Novartis, Pfizer, Sanofi, AstraZeneca; Financial Interests, Institutional, Research Funding: BD Bioscience, Volition; Financial Interests, Institutional, Advisory Board: Celgene, Chugai, Janssen, Lilly, Roche, Takeda; Financial Interests, Personal, Advisory Role: Health Event; Financial Interests, Personal, Advisory Board: Maat Pharma, Pierre Fabre. F. Brellier: Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. Y. Khalife: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Family member is an employee: AstraZeneca. All other authors have declared no conflicts of interest. Resources from the same session1260P - Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal studyPresenter: Ludovic Doucet Session: Poster session 05 1261P - Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutationsPresenter: Jie Wang Session: Poster session 05 1262P - Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistancePresenter: Tijmen van der Wel Session: Poster session 05 1263P - Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)Presenter: Hiroshige Yoshioka Session: Poster session 05 1264P - Real-world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical needPresenter: John Heymach Session: Poster session 05 1265P - A promising MET-EGFR bispecific nanobody-drug conjugate therapy for multiple solid tumoursPresenter: xianghai Cai Session: Poster session 05 1266P - Interim analysis from the multicenter ROSE study: Radiation during osimertinib treatment safety and efficacy cohortPresenter: Amanda Tufman Session: Poster session 05 1267P - Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational studyPresenter: Naoto Takase Session: Poster session 05 1268P - Concordances assessment between MET-positive circulating tumour cells and disease progression in patients with EGFR mutated NSCLCPresenter: Jieun Park Session: Poster session 05 1269P - Preventing infusion-related reactions with intravenous amivantamab: Updated results from SKIPPirr, a phase II studyPresenter: Luis Paz-Ares Session: Poster session 05 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| ||||||